many studies have explored the effects of immunotherapy, alone or in combination with conventional therapies, on both experimental and human cancers. evidence has been provided that combined treatments with thymosin alpha 1 (T alpha 1) and low doses of interferon (IFN) or interleukin (IL)-2 are highly effective in restoring several immune responses depressed by tumor growth and/or cytostatic drugs. In addition, when combined with specific chemotherapy, they are able to increase the anti-tumor effect of chemotherapy while markedly reducing the general toxicity of the treatment. the advantages of using this combined chemo-immunotherapeutic approach in experimental and human cancers are reviewed in this issue.

Garaci, E., Pica, F., Rasi, G., Favalli, C. (2000). Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application. INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 22(12), 1067-1076 [10.1016/S0192-0561(00)00075-8].

Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application

GARACI, ENRICO;PICA, FRANCESCA;Rasi, G;FAVALLI, CARTESIO
2000-12-01

Abstract

many studies have explored the effects of immunotherapy, alone or in combination with conventional therapies, on both experimental and human cancers. evidence has been provided that combined treatments with thymosin alpha 1 (T alpha 1) and low doses of interferon (IFN) or interleukin (IL)-2 are highly effective in restoring several immune responses depressed by tumor growth and/or cytostatic drugs. In addition, when combined with specific chemotherapy, they are able to increase the anti-tumor effect of chemotherapy while markedly reducing the general toxicity of the treatment. the advantages of using this combined chemo-immunotherapeutic approach in experimental and human cancers are reviewed in this issue.
dic-2000
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA
Settore MEDS-03/A - Microbiologia e microbiologia clinica
English
Con Impact Factor ISI
Animals; Neoplasms; Combined Modality Therapy; Antineoplastic Agents; Immunotherapy; Humans; Thymosin; Adjuvants, Immunologic
Garaci, E., Pica, F., Rasi, G., Favalli, C. (2000). Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application. INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 22(12), 1067-1076 [10.1016/S0192-0561(00)00075-8].
Garaci, E; Pica, F; Rasi, G; Favalli, C
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
149-(2000) Int J of Immunopharmacol.pdf

solo utenti autorizzati

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 370.79 kB
Formato Adobe PDF
370.79 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/54320
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 42
  • ???jsp.display-item.citation.isi??? 37
social impact